NASDAQ:SPRB • US85209E2081
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SPRUCE BIOSCIENCES INC (SPRB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-10 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-23 | Oppenheimer | Initiate | Outperform |
| 2025-12-03 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-11-11 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-10-28 | JMP Securities | Upgrade | Market Perform -> Market Outperform |
| 2025-10-21 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2025-04-16 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-12-12 | Guggenheim | Reiterate | Neutral -> Neutral |
| 2024-12-11 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-12-11 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-12-11 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-11-12 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-08-13 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-06-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-06-05 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-14 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-03-14 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-03-14 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2024-03-14 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-03-14 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-03-14 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.089M | 4.911M -51.32% | -100.00% | 51.17M | 10.551M -79.38% | 34.374M 225.79% | -100.00% | 27.596M | 84.181M 205.05% | 142.64M 69.44% | ||
| EBITDA YoY % growth | -47.21M -12.40% | -51.923M -9.98% | -56.105M -8.05% | -88.787M 34.96% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -47.28M -12.38% | -51.993M -9.97% | -56.151M -8.00% | -34.919M 34.97% | -49.028M -34.28% | -49.935M -1.85% | -14.586M 70.79% | -14.687M -0.69% | 12.241M 183.35% | 66.621M 444.24% | 122.7M 84.18% | |
| Operating Margin | N/A | -515.34% | -1,143.37% | N/A | -95.81% | -473.27% | -42.43% | N/A | 44.36% | 79.14% | 86.02% | |
| EPS YoY % growth | -147.00 -8.89% | -94.50 35.71% | -96.00 -1.59% | -21.68 77.42% | -24.46 -12.84% | -16.95 30.70% | -1.03 93.95% | -0.14 86.07% | 0.13 192.86% | 0.60 353.85% | 1.06 76.27% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -8.99 62.53% | -9.17 -161.90% | 1.26 108.62% | -7.62 6.41% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.152M 23.05% | -9.384M -248.59% | -11.526M -40.07% | -13.056M -17.62% |
All data in USD
10 analysts have analysed SPRB and the average price target is 209.87 USD. This implies a price increase of 242.8% is expected in the next year compared to the current price of 61.22.
SPRUCE BIOSCIENCES INC (SPRB) will report earnings on 2026-04-13, after the market close.
The consensus EPS estimate for the next earnings of SPRUCE BIOSCIENCES INC (SPRB) is -8.99 USD and the consensus revenue estimate is 0 USD.
The expected long term growth rate for SPRUCE BIOSCIENCES INC (SPRB) is 26.64%.